KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Share-based Compensation (2016 - 2025)

Amgen has reported Share-based Compensation over the past 13 years, most recently at $125.0 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $125.0 million for Q4 2025, down 6.72% from a year ago — trailing twelve months through Dec 2025 was $494.0 million (down 6.79% YoY), and the annual figure for FY2025 was $494.0 million, down 6.79%.
  • Share-based Compensation for Q4 2025 was $125.0 million at Amgen, down from $127.0 million in the prior quarter.
  • Over the last five years, Share-based Compensation for AMGN hit a ceiling of $161.0 million in Q4 2023 and a floor of $47.0 million in Q1 2023.
  • Median Share-based Compensation over the past 3 years was $126.0 million (2025), compared with a mean of $121.2 million.
  • Biggest five-year swings in Share-based Compensation: surged 119.15% in 2024 and later dropped 17.48% in 2025.
  • Amgen's Share-based Compensation stood at $161.0 million in 2023, then dropped by 16.77% to $134.0 million in 2024, then decreased by 6.72% to $125.0 million in 2025.
  • The last three reported values for Share-based Compensation were $125.0 million (Q4 2025), $127.0 million (Q3 2025), and $157.0 million (Q2 2025) per Business Quant data.